SPECT-based Prediction and Evaluation of CRT Efficacy in CHF
MIBGinCRT
Single-photon Emission Computed Tomography for Prediction and Evaluation of Cardiac Resynchronization Therapy Efficacy in Chronic Heart Failure Patients
1 other identifier
interventional
60
1 country
1
Brief Summary
This study evaluates the state of the cardiac sympathetic activity and the severity of ventricular dyssynchrony in chronic heart failure patients and assesses the capabilities of radionuclide indication methods in determining the prognosis and evaluating the results of cardiac resynchronization therapy in chronic heart failure patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2017
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2017
CompletedFirst Submitted
Initial submission to the registry
September 11, 2018
CompletedFirst Posted
Study publicly available on registry
September 12, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2020
CompletedSeptember 30, 2020
September 1, 2019
1.9 years
September 11, 2018
September 29, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
CRT response
ESV decreasing equal or more than 15%
One year
Study Arms (1)
123I-MIBG CZT SPECT
OTHERPatients with ischemic and non-ischemic heart failure with indications for CRT. Assessment of cardiac sympathetic innervation by 123IMIBG CZT SPECT.
Interventions
Assessment of cardiac sympathetic innervation by 123I-MIBG CZT SPECT
Eligibility Criteria
You may qualify if:
- Chronic heart failure NYHA III and IV class
- LVEF ≤ 35 %
- QRS ≥ 150 ms on ECG
- The presence of LBBB on ECG
- Sinus rhythm
- Optimal pharmacological treatment of heart failure
You may not qualify if:
- Contraindications to SPECT due to hypersensitivity to radiopharmacuticals such as 2-methoxy-isobutyl-isonitrile-(99mTc) and (123)I-Meta-iodobenzylguanidine or any of the excipients
- Pregnancy
- Breastfeeding
- Refusal to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Cardiology Research Institute, Tomsk NRMC
Tomsk, Tomsk Oblast, 634012, Russia
Related Publications (1)
Atabekov T, Korepanov V, Krivolapov S, Khlynin M, Afanasiev S, Golubenko M, Batalov R, Popov S. Mitochondrial DNA Polymorphisms of Peripheral Blood Mononuclear Cells Associated with Sustained Ventricular Tachycardia in Patients with Cardioverter-Defibrillator Implantation Indications. Rev Cardiovasc Med. 2025 Mar 17;26(3):26744. doi: 10.31083/RCM26744. eCollection 2025 Mar.
PMID: 40160580DERIVED
Study Officials
- STUDY DIRECTOR
Sergey V Popov, MD, PhD
Tomsk NRMC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 11, 2018
First Posted
September 12, 2018
Study Start
September 1, 2017
Primary Completion
August 1, 2019
Study Completion
August 1, 2020
Last Updated
September 30, 2020
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will not share